

Immunology and Treatment of Type 1 Diabetes

Special Edition of The Review of Diabetic Studies, Winter 2012/2013

Table of Contents

Chapter I. Pathogenesis.....	135
I.1 Genetic Analysis of Type 1 Diabetes: Embryonic Stem Cells as New Tools to Unlock Biological Mechanisms in Type 1 Diabetes by Nick Holmes & Anne Cooke.....	137
1. NOD congenic mice.....	137
2. Correlating genetic, phenotypic, and functional variation.....	138
3. Introduction of targeted mutations from other genetic backgrounds.....	140
4. RNA interference approaches.....	140
5. The development of ES cells from NOD mice.....	141
6. Genetic manipulation of NOD ES cells.....	142
7. The future potential of ES cells and alternative targeting approaches in type 1 diabetes.....	143
I.2 Pathogenic Mechanisms in Type 1 Diabetes: The Islet is Both Target and Driver of Disease by Kate L. Graham, Robyn M. Sutherland, Stuart I. Mannering, Yuxing Zhao, Jonathan Chee, Balasubramanian Krishnamurthy, Helen E. Thomas, Andrew M. Lew & Thomas W.H. Kay.....	148
1. Introduction.....	148
1.1 T lymphocytes destroy beta-cells.....	149
1.2 Function of other immune cells in beta-cell destruction.....	149
2. The pancreatic lymph node	151
2.1 Autoreactive T cells are primed in the pancreatic lymph nodes.....	151
2.2 Insulin is the primary antigen in NOD mice.....	151
2.3 Antigen specificity of autoreactive T cells in human type 1 diabetes.....	152
3. Migration of effector cells from lymph nodes to islets	153
3.1 Islet-infiltrating T cells are antigen-specific.....	153
3.2 Entry of immune cells into the islets.....	153
4. Insulinitis.....	153
4.1 NOD mouse insulinitis.....	153
4.2 Insulinitis in human islets.....	154
5. Mechanisms of beta-cell destruction.....	156
5.1 The requirement for CD8 ⁺ T cells.....	156
5.2 Perforin and granzymes released by CTLs are the dominant effectors of beta-cell destruction.....	156
5.3 The Fas/FasL pathway is a minor effector of beta-cell destruction.....	157
5.4 Effector mechanisms utilized by human auto-reactive CTLs.....	157
5.5 Pro-inflammatory cytokines are critical regulators of effector function, but they are not important effectors of beta-cell destruction.....	157
5.6 The function of human autoreactive CD4 ⁺ T cells.....	158
5.7 The emerging role of macrophages and NK cells.....	159
6. The function of the islet environment.....	159
6.1 Immune regulatory mechanisms within islets fail to control progression of insulinitis.....	159
6.2 Antigen presentation within the islet environment.....	161
6.3 The local T cell response is driven by ongoing recruitment and intra-islet proliferation.....	161
6.4 CTLs are armed within islets.....	161
6.5 Post beta-cell destruction events.....	162
7. Summary and conclusions	163
I.3 Comparative Genetics: Synergizing Human and NOD Mouse Studies for Identifying Genetic Causation of Type 1 Diabetes by John P. Driver, Yi-Guang Chen & Clayton E. Mathews.....	169
1. Introduction.....	169
2. Use of NOD mice in preclinical trials.....	169
3. Similarities in genetic causation.....	171
4. HLA and MHC: master genes for susceptibility.....	171

4.1 mt-ND2 and mt-Nd2.....	174
4.2 Homology in gene systems and pathways in genetic pathogenesis.....	175
5. Gene-gene interactions and epistatic effects.....	176
6. Improving the efficiency of candidate gene identification.....	178
6.1 NOD embryonic stem cells.....	178
6.2 Zinc finger nucleases (ZFN).....	179
6.3 Transcription activator-like effector nucleases (TALEN).....	179
6.4 RNA interference.....	179
6.5 Retrogenic mice.....	180
6.6 Next generation sequencing.....	180
7. Conclusions.....	181
I.4 Protein Tyrosine Phosphatases and Type 1 Diabetes: Genetic and Functional Implications of PTPN2 and PTPN22 by Karen Cerosaletti & Jane H. Buckner.....	188
1. Introduction.....	188
2. PTPN22.....	189
2.1 Genetic studies and broad association of PTPN22 1858T with autoimmunity.....	189
2.2 Known function of lymphocyte tyrosine phosphatase (LYP).....	189
2.3 Dissecting the functional impact of LYP R620W on lymphocytes.....	190
2.4 Function of the LYP R620W variant deduced from murine models of PEP and PEP R619W.....	190
2.5 Assessment of the role of LYP and the LYP R620W variant in human cells.....	191
2.6 Caveats related to studies of PTPN22 in human lymphocytes.....	192
2.7 LYP's role in the development of T1D.....	192
3. PTPN2.....	193
3.1 Genetic association of PTPN2 with autoimmunity.....	193
3.2 Known function of PTPN2.....	193
3.3 Functional impact of the PTPN2 risk variant.....	194
3.4 Role of PTPN2 in autoimmunity deduced from murine models of PTPN2 deficiency.....	194
3.5 The role of PTPN2 in the development and progression of T1D.....	196
4. Conclusions.....	197
I.5 From Markers to Molecular Mechanisms: Type 1 Diabetes in the Post-GWAS Era by Alan G. Baxter & Margaret A. Jordan.....	201
1. Clinical definition type 1 diabetes.....	201
2. Familial risk of type 1 diabetes.....	201
3. Association of HLA with type 1 diabetes.....	201
4. Association of other candidate genes with type 1 diabetes.....	203
4.1 INS.....	203
4.2 PTPN22.....	203
5. Linkage studies of type 1 diabetes.....	203
5.1 FGF3/LRP5.....	204
5.2 Gene/gene interactions.....	204
5.3 SUMO4.....	205
5.4 CTLA4.....	205
5.5 CD25.....	205
5.6 Other loci.....	206
5.7 Linkage analyses of combined datasets and the limits of linkage analyses.....	206
6. Genome-wide association studies (GWAS) of type 1 diabetes.....	207
6.1 IFIH1.....	208
6.2 SH2B3.....	208
6.3 ERBB3.....	208
6.4 CLEC16A.....	208
6.5 PTPN2.....	209
6.6 CD226.....	209
6.7 BACH2.....	211
6.8 PRKCQ.....	211
6.9 CTSH.....	211
6.10 C1QTNF6.....	211
6.11 IL10.....	211
6.12 CD69.....	211
6.13 IL27.....	212
6.14 GLIS3.....	212
7. From location to molecular mechanisms: the missing heritability problem.....	212

7.1 Misdiagnosis.....	212
7.2 Familial environmental differences.....	212
7.3 Gene/environment interactions.....	213
7.4 Epistasis: gene/gene interactions.....	213
7.5 Epigenetic inheritance.....	213
7.6 Inheritance of copy number variations.....	213
7.7 Ineffective haplotype tagging.....	213
7.8 Rare variants.....	214
7.9 Common variants of low effect.....	213
7.10 Missing association.....	215
8. From genes to function.....	215
I.6 Novel Biomarkers in Type 1 Diabetes by Yulan Jin & Jin-Xiong She.....	224
1. Introduction.....	224
2. Prediction of T1D risk using genetic markers.....	225
3. Transcriptomic biomarkers for T1D.....	227
4. Proteomic biomarkers for T1D.....	229
5. Conclusions.....	231
I.7 Metabolomics in the Studies of Islet Autoimmunity and Type 1 Diabetes by Matej Oresic.....	236
1. Introduction.....	236
2. Analytical strategies for metabolomics.....	237
3. Factors influencing the metabolome.....	239
4. Metabolomic approaches to study type 1 diabetes.....	241
5. The metabolome as a factor in the progression to type 1 diabetes.....	243
6. Conclusions and future perspectives.....	244
Chapter II. Prevention.....	249
II.1 Gut Microbiota and Type 1 Diabetes by Outi Vaarala.....	251
1. Introduction.....	251
2. Gut microbiota and autoimmune diabetes in animal models.....	252
3. Interaction between diet, enteral infections, and bacterial microflora in the gut.....	253
4. Less diversity and abundance of Bacteroidetes in human type 1 diabetes.....	254
5. Low abundance of butyrate-producing bacteria in children with beta-cell autoimmunity.....	255
6. Causality and functional effects of altered microbiota in type 1 diabetes.....	256
7. Outlook on future research.....	256
II.2 Virus Infections as Potential Targets of Preventive Treatments for Type 1 Diabetes by Noora Nurminen, Sami Oikarinen & Heikki Hyöty.....	260
1. Background.....	260
2. Lessons from other enterovirus diseases and the pathogenesis of type 1 diabetes.....	261
3. How potential diabetogenic effects of enteroviruses can be detected in human studies.....	263
3.1 Role of non-invasive and invasive infection.....	263
3.2 The low attack rate of enteroviruses.....	263
3.3 Importance of distinguishing EV subtypes from each other.....	263
3.4 Possible viral persistence.....	264
3.5 Role of host's susceptibility factors.....	264
3.6 Population effect.....	265
3.7 Recruitment of study cohorts.....	265
3.8 Detecting diabetogenic effects of EVs – summary.....	265
4. How to prove causality?.....	266
5. Current scenarios in the development of EV vaccines to treat type 1 diabetes.....	267
5.1 Type of diabetogenic EVs.....	267
5.2 Safety of the vaccine.....	267
5.3 Strength of evidence.....	267
5.4 T1D susceptibility attributable to EV infections.....	268
5.5 Current stage of development of an EV vaccine.....	268
6. Conclusions.....	268

II.3 Helminth Infection and Type 1 Diabetes by <i>Paola Zaccone & Samuel W. Hall</i>	272
1. Introduction.....	272
2. Ancient “frenemies”.....	273
3. Prevention experiments in the non-obese diabetic mouse model of T1D.....	277
4. Immunity to helminthes.....	279
5. Mechanisms of helminth-mediated diabetes protection.....	280
6. Extending the hygiene hypothesis.....	281
7. Towards translation.....	281
8. Conclusions.....	282
Chapter III. Re-establishing Tolerance	287
III.1 Type 1 Diabetes Therapy Beyond T Cell Targeting: Monocytes, B Cells, and Innate Lymphocytes by <i>F. Susan Wong & Li Wen</i>	289
1. Introduction.....	289
2. Monocytes, macrophages, and dendritic cells.....	290
2.1 Genetics.....	291
2.2 Studies in animal models.....	291
2.3 Studies in humans.....	291
2.4 Potential targets.....	292
3. B cells.....	295
3.1 Studies in animal models.....	295
3.2 Studies in humans.....	295
3.3 Other strategies for targeting B cells.....	296
4. Gamma delta T cells.....	297
5. Natural killer cells.....	297
6. Natural killer T cells.....	299
7. Concluding remarks.....	299
III.2 Targeted Antigen Delivery to DEC-205⁺ Dendritic Cells for Tolerogenic Vaccination by <i>Cathleen Petzold, Sonja Schallenberg, Joel N.H. Stern & Karsten Kretschmer</i>	305
1. Introduction.....	305
2. Dendritic cells in immune tolerance.....	306
3. Targeted Ag delivery to DEC-205 ⁺ DCs in vivo.....	307
4. DEC-205 ⁺ DC targeting to enhance Ag-specific T cell immunity.....	308
5. DEC-205 ⁺ DC targeting to promote Ag-specific T cell tolerance.....	309
5.1 Recessive tolerance.....	309
5.2 Dominant tolerance.....	309
6. Extrathymic Foxp3 ⁺ Treg cell induction in nonmanipulated mice.....	309
7. Stability and function of DEC-205 ⁺ DC-targeted Foxp3 ⁺ Treg cells.....	311
8. Tolerogenic DEC-205 ⁺ DC vaccination in autoimmunity.....	312
8.1 Autoimmune diabetes.....	312
8.2 Autoimmune encephalomyelitis.....	312
9. Ag-specific induction of T cell tolerance: a unique property of DEC-205 ⁺ DCs?.....	314
10. Conclusions.....	314
III.3 Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes by <i>Suchitra Prasad, Dan Xu & Stephen D. Miller</i>	319
1. Introduction.....	319
2. Mechanism of Ag-ECDI-SP tolerance.....	320
3. Ag-ECDI-SP tolerance in T1D.....	321
3.1 Insulin-ECDI-SP in NOD mice.....	321
3.2 p31-ECDI-SP in adoptive transfer of BDC2.5 TCR transgenic cells.....	322
3.3 Ag-ECDI-SP in “humanized” NOD.β2mnull.HHD model of T1D.....	322
3.4 Ag-ECDI-SP in islet transplantation.....	323
3.5 Ag-ECDI-PLGA nanoparticles induce tolerance.....	323

4. Perspectives.....	325
III.4 Clinical Potential of Antigen-Specific Therapies in Type 1 Diabetes by <i>Ken T. Coppieters, Birgit Sehested Hansen & Matthias G. von Herrath</i>	328
1. Immune suppression in T1D: the sledgehammer approach.....	328
2. Immune modulation in T1D: improved safety, reduced efficacy.....	329
3. The concept of antigen-specific tolerance.....	329
4. Antigen-specific tolerance in T1D: excellent safety, but efficacy to be improved.....	330
5. Examples of past and current antigen-specific therapy trials in T1D.....	331
5.1 Oral antigen administration.....	331
5.2 Nasal antigen administration.....	332
5.2 Subcutaneous antigen administration.....	332
6. The future of antigen-specific therapy.....	333
III.5 Interleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes by <i>Thomas Mandrup-Poulsen</i>	338
1. Introduction.....	338
2. Cytokines and type 1 diabetes: no lack of candidate targets.....	339
3. TNF α antagonism.....	340
3.1 Biology of TNF α	340
3.2 TNF α antagonists.....	341
3.3 Type 1 diabetes.....	341
4. Interleukin-1 antagonism.....	341
4.1 Biology of IL-1.....	341
4.2 IL-1 antagonists.....	342
4.3 Type 1 diabetes.....	343
5. Conclusions and perspectives.....	345
III.6 In Vivo Delivery of Nucleic Acid-Formulated Microparticles as a Potential Tolerogenic Vaccine for Type 1 Diabetes by <i>Valentina Di Caro, Nick Giannoukakis & Massimo Trucco</i>	348
1. Introduction.....	348
2. Dendritic cells as immunoregulators.....	349
3. Tolerogenic dendritic cells as cell therapy for type 1 diabetes.....	352
4. Dendritic cell-targeting microparticles.....	353
5. Conclusion and perspective.....	355
Chapter IV. Clinical Trials	357
IV.1 Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience by <i>Mario R. Ehlers & Gerald T. Nepom</i>	359
1. Introduction.....	359
2. ITN trials in new-onset T1D.....	360
2.1 The AbATE trial (anti-CD3 mAb).....	361
2.2 The IL-2/rapa trial.....	363
2.3 The START trial using ATG.....	364
2.4 The RETAIN trial (α 1-antitrypsin).....	365
2.5 The T1DAL trial with alefacept.....	365
3. What have we learned: insights and challenges.....	365
4. Future directions.....	366
4.1 Combination therapies.....	366
4.2 Novel trial designs.....	367
5. Conclusions.....	369
IV.2 CD3 Monoclonal Antibodies: A First Step Towards Operational Immune Tolerance in the Clinic by <i>Lucienne Chatenoud & Herman Waldmann</i>	372
1. Introduction.....	372
2. Clinical development of CD3 antibodies: a story spanning more than 20 years.....	374

2.1 The first experiences in clinical transplantation.....	374
2.2 CD3 antibodies as mediators of immune tolerance in primed hosts: the proof-of-concept in experimental autoimmunity.....	375
2.3 Mechanistic considerations.....	375
3. Clinical trials using CD3 monoclonal antibodies in autoimmune diabetes.....	376
4. Conclusions: how to assess the results from clinical trials?.....	378
Chapter V. Beta-Cell Replacement.....	383
V.1 Islet Transplantation in Type 1 Diabetes: Update on Ongoing Challenges, Refined Procedures, and Long-Term Outcome by <i>A.M. James Shapiro</i>	385
1. Overview perspective.....	385
2. Donor selection, pancreas procurement, islet isolation and culture.....	388
3. Clinical islet transplantation.....	389
3.1 Selection of patients.....	389
3.2 Intraportal access.....	390
4. Risks with islet transplantation.....	391
5. Immunosuppression for islet transplantation.....	392
5.1 Induction of immunosuppression.....	393
5.2 Anti-inflammatory and beta-cell-preserving strategies.....	393
5.3 Maintenance immunosuppression.....	394
5.4 Long-term outcomes.....	395
6. Impact of islet transplant upon secondary complications.....	395
7. Alternatives to islet transplantation.....	396
8. Summary and conclusions.....	397
V.2 Islet Neogenesis: A Possible Pathway for Beta-Cell Replenishment by <i>Susan Bonner-Weir, Lili Guo, Wan-Chun Li, Limor Ouziel-Yahalom, Philippe Lysy, Gordon C. Weir & Arun Sharma</i>	407
1. Introduction.....	407
2. Definition of neogenesis.....	408
3. Neogenesis during the neonatal period in rodents.....	408
4. Experimental models of neogenesis.....	410
4.1 Partially pancreatectomized rodents.....	410
4.2 Partial duct ligation in rodents.....	410
4.3 Selected examples of other transgenic mice with induced neogenesis.....	411
5. Postnatal expansion of the endocrine pancreas in humans.....	412
5.1 Evidence of compensatory expansion in the adult human pancreas.....	412
5.2 Pancreas of type 1 diabetes patients.....	413
6. Conclusions.....	413

